Bicycle Therapeutics plc American Depositary Shares
BCYC
BCYC: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
moreShow BCYC Financials
Recent trades of BCYC by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BCYC's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions Jun. 06, 2017
-
Patent Title: Multispecific peptides Jun. 06, 2017
-
Patent Title: Connector compound peptide phage display May. 23, 2017
-
Patent Title: Structured peptide processing May. 09, 2017
-
Patent Title: Peptide libraries Dec. 13, 2016
-
Patent Title: Structured peptide processing Jul. 15, 2014
-
Patent Title: Multispecific peptides Apr. 01, 2014
-
Patent Title: Methods and compositions Mar. 25, 2014
Federal grants, loans, and purchases
Followers on BCYC's company Twitter account
Number of mentions of BCYC in WallStreetBets Daily Discussion
Recent insights relating to BCYC
Recent picks made for BCYC stock on CNBC
ETFs with the largest estimated holdings in BCYC
Flights by private jets registered to BCYC